Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no ...
Sight Sciences, Inc. has announced that new data on the OMNI® Surgical System will be presented at the 2025 American Glaucoma Society Annual Meeting, showcasing significant clinical outcomes in ...
A Meta-Analysis of 22 Studies, and Data from the IRIS ® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication ...
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing ...
MENLO PARK, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc (SGHT). (Nasdaq: SGHT) , an eyecare technology company focused on developing and commercializing innovative, interventional ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A study looked at real-world outcomes with Omni, Hydrus, ...
MENLO PARK, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. According to Campbell, 24-month study outcomes showed an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results